Web-based tool ups informed choice in rheumatoid arthritis

Web-Based tool ups informed choice in rheumatoid arthritis

(HealthDay) -- A decision support tool effectively communicates the risks and benefits of biologic therapy to patients with rheumatoid arthritis (RA), increasing their likelihood of making an informed choice about treatment, according to a study published online March 5 in Arthritis Care & Research.

Liana Fraenkel, M.D., M.P.H., of the Yale University School of Medicine in New Haven, Conn., and associates developed a Web-based to inform patients with RA about the risks and benefits of biologic therapy with disease modifying anti-rheumatic drugs. One hundred four patients were interviewed and the tool was assessed for its efficacy in improving knowledge related to biologics, clarity of values, willingness to take a biologic, and informed choice.

The researchers found that, after viewing the tool, both knowledge and willingness to take a biologic increased significantly. There was also a significant improvement in perceived knowledge and value clarity, after viewing the tool. There was a substantial increase in the proportion of subjects making an informed, value-concordant choice (up from 35 to 64 percent).

"A tool designed to effectively communicate the risks and benefits associated with biologic therapy increased knowledge, patient willingness to escalate care, and the of making an informed choice," the authors write. "The results of this study support the need for a clinical trial to examine the impact of the tool in clinical practice."

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

New biologic drug is effective against rheumatoid arthritis

date Oct 06, 2009

Abatacept, a member of a new class of drug that targets immune cells to treat rheumatoid arthritis (RA), is effective against RA, according to a new Cochrane Systematic Review. The review examines recent trials to assess ...

Recommended for you

New test could predict arthritis drug failure in patients

date Jul 03, 2015

A study of 311 patients by The University of Manchester has found that it may be possible to predict early which rheumatoid arthritis (RA) patients will fail to respond to the biologic drugs given to treat them. These findings ...

About 8 percent of SLE patients have pulmonary HTN

date Jun 23, 2015

(HealthDay)—About 8 percent of patients with systemic lupus erythematosus (SLE) have pulmonary hypertension (PH), and serum uric acid (UA) has reasonable accuracy for predicting PH, according to a study ...

Early age of menopause linked to seropositivity in RA

date Jun 17, 2015

(HealthDay)—In women with early rheumatoid arthritis (RA), early age at menopause is associated with seropositivity, according to a study published in the May issue of Arthritis Care & Research.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.